KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial. PMID 40758955 · J Clin Oncol · 2025-Oct Study meets criteria for oncology, human, randomized, phase III, and time-to-event endpoint, but the intervention is a radiotherapy technique (focal boost) without a drug component, thus failing the drug-intervention criterion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effectiveness of an active behavioural physiotherapy intervention (ABPI) for chronic non-specific neck pain: an internal pilot cluster-randomised double-blind clinical trial. PMID 40753854 · Musculoskelet Sci Pract · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 study. PMID 40750941 · Int J Clin Oncol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial. PMID 40750932 · Nat Med · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 6 Figure · 27 Panel · risk unclear
Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer. PMID 40745221 · Br J Cancer · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term tolerability and efficacy of adjunctive brivaracetam in pediatric patients with generalized-onset seizures: Subgroup analysis of an open-label, follow-up trial. PMID 40737960 · Epilepsy Behav · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
FOLFIRINOX or FOLFOX for locally advanced or metastatic small bowel adenocarcinoma: PRODIGE 86 - FFCD-GONO - ENGIC 02 - FOLFIRINOX SBA phase II randomized trial. PMID 40730749 · Dig Liver Dis · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial. PMID 40726438 · Diabetes Obes Metab · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial. PMID 40712928 · Radiother Oncol · 2025-Oct The record describes a secondary, longitudinal analysis of patient-reported adverse events and quality of life from the IMPORT HIGH phase III randomized trial of radiotherapy techniques in breast cancer. It does not report a primary or key secondary time-to-event efficacy endpoint (like OS, PFS, DFS, or Kaplan-Meier/HR for such an endpoint). The intervention is radiotherapy, not a drug. Therefore, it does not meet the eligibility criteria for a drug-containing intervention trial with a time-to-event efficacy endpoint.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6. PMID 40704485 · Diabetes Obes Metab · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase 3 Active-Controlled Trial of Liposomal Bupivacaine via Adductor Canal Block for Total Knee Arthroplasty. PMID 40701284 · J Arthroplasty · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial. PMID 40700861 · Mult Scler Relat Disord · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The Importance of a Pre-treatment Baseline When Screening Patients for Breast-Cancer-Related Lymphedema. PMID 40699530 · Ann Surg Oncol · 2025-Oct The record describes a randomized trial in breast cancer (oncology, human, randomized, original primary results) but the intervention is bioimpedance spectroscopy screening (a diagnostic/prophylactic management strategy) not a drug-containing therapy. The primary endpoint is progression to chronic lymphedema (a clinical outcome), not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The abstract does not report Kaplan-Meier curves, hazard ratios, or any time-to-event analysis, focusing instead on cross-sectional baseline assessments.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma. PMID 40690727 · J Clin Oncol · 2025-Oct The study is an oncology, human, Phase III randomized trial with a primary time-to-event endpoint (DFS). However, it compares surgical interventions and does not involve a drug-containing intervention, which is a required criterion for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study. PMID 40690163 · Rheumatol Ther · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy. PMID 40686005 · Prostate · 2025-Oct This is a secondary analysis of a Phase III randomized trial (NRG/RTOG 9601) examining the prognostic impact of lymph node yield. While the underlying trial meets oncology, human, randomized, Phase III, and time-to-event criteria, and includes a drug intervention (RT + bicalutamide), this specific publication is not a primary or definitive report of the trial's original efficacy results. It is a subgroup/prognostic analysis focusing on a pathological variable, not the primary comparison of treatment arms.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial. PMID 40681915 · CNS Drugs · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Inhaled isoflurane for sedation of mechanically ventilated children in intensive care (IsoCOMFORT): a multicentre, randomised, active-control, assessor-masked, non-inferiority phase 3 trial. PMID 40680761 · Lancet Respir Med · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant focal epilepsies treated in the Expanded Access Program. PMID 40673944 · Epilepsia · 2025-Oct 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Radiotherapy combined with anlotinib in locoregional recurrent esophageal squamous cell carcinoma after radical surgery: a prospective, Phase II clinical trial. PMID 40670666 · Br J Cancer · 2025-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis. PMID 40652442 · Neurol Ther · 2025-Oct The record describes a study in relapsing multiple sclerosis, not a human malignant neoplasm (oncology). The primary/time-to-event efficacy endpoint is not OS, PFS, DFS, EFS, RFS, TTP, or another classic oncology time-to-event outcome. The study is a randomized, Phase III trial with a drug intervention, but fails the core oncology and endpoint criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase II pilot randomized controlled trial of an integrated stepped collaborative care intervention for patients awaiting kidney transplantation (CARES-transplant). PMID 40643797 · J Behav Med · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial. PMID 40639766 · Radiother Oncol · 2025-Oct The trial is a randomized Phase III oncology trial, but it fails two critical inclusion criteria: (1) the primary/key secondary endpoint is not a standard time-to-event efficacy endpoint (it is a quality-of-life/toxicity endpoint), and (2) the intervention is non-drug only (radiation therapy). Therefore, it is not eligible for this cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Results of a Randomized Augmented Intensification Phase in Acute Lymphoblastic Leukemia in Children in Argentina: GATLA 2010 ALL IC Trial. PMID 40635183 · Pediatr Blood Cancer · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma. PMID 40633690 · Ann Oncol · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? PMID 40633461 · Breast · 2025-Oct The record is excluded because it is a secondary, prognostic-biomarker analysis of a Phase III trial, not the original report of the trial's primary or key secondary time-to-event efficacy endpoint. The required original-result report of the trial's efficacy analysis is not provided.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial. PMID 40632620 · Leuk Lymphoma · 2025-Oct The study is an oncology trial with a drug intervention and reports original primary results. However, it is explicitly a Phase 1/2 trial (not Phase III/IIIb) and is single-arm (not randomized). The abstract reports response rates (ORR, CR) as the primary efficacy endpoints, with no mention of a time-to-event endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). Therefore, it does not meet the required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201. PMID 40632607 · Leuk Lymphoma · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type no_km 0 Figure · 0 Panel · risk not_applicable
The Growing Potential of Thermal Ablation for Colorectal Liver Metastases. PMID 40616649 · J Surg Oncol · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma. PMID 40613748 · CPT Pharmacometrics Syst Pharmacol · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: a systematic review and meta-analysis. PMID 40610712 · J Thromb Thrombolysis · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Undertreated Volume and Tumor Morphology as Predictors of Outcome Following Thermal Ablation of 3-7-cm Hepatocellular Carcinoma. PMID 40609677 · J Vasc Interv Radiol · 2025-Oct The study is an original analysis from a randomized trial but does not present a drug-containing intervention as the primary focus of this report (ThermoDox is mentioned as part of the prior trial, but this analysis is a retrospective sub-study on imaging predictors). More critically, the primary endpoints are predictors of local recurrence and survival via univariate/multivariate analysis (p-values), not a formal time-to-event efficacy report with Kaplan-Meier curves, hazard ratios, or survival probabilities as the primary outcome. The 'survival' outcome is mentioned as a correlation, not as a reported time-to-event endpoint with event rates or curves. Therefore, it does not meet the time-to-event efficacy requirement for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial. PMID 40578381 · Lancet Respir Med · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease. PMID 40575474 · J Pharm Technol · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities. PMID 40555305 · Ann Allergy Asthma Immunol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized, Double-Blind Crossover Study of Change in Post-Dose Lung Function with Hydrofluoroolefin-1234ze, a Next-Generation Propellant for Metered Dose Inhalers, in Participants with Asthma. PMID 40551410 · J Aerosol Med Pulm Drug Deliv · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Renal resistance trajectories during hypothermic machine perfusion in kidneys donated after circulatory death: Associations with donor characteristics and posttransplant outcomes-An analysis of COMPARE trial data. PMID 40550469 · Am J Transplant · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial. PMID 40545499 · Chin J Integr Med · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial. PMID 40544121 · Eur Urol · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial. PMID 40543844 · Ann Oncol · 2025-Oct 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study. PMID 40543832 · Fertil Steril · 2025-Oct This is a randomized, double-blind, placebo-controlled Phase 3 trial of a drug (linzagolix) for uterine fibroids (non-cancerous, benign neoplasm). The primary efficacy endpoint is a categorical response (reduction in heavy menstrual bleeding to <80 mL and >50% reduction), not a time-to-event outcome such as OS, PFS, DFS, RFS, TTP, or survival analyzed via Kaplan-Meier/HR. Therefore, it does not meet the oncology or time-to-event criteria for inclusion in the cohort.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial. PMID 40541863 · Ann Oncol · 2025-Oct The report is a secondary analysis of health-related quality of life from a Phase III randomized trial. It does not present primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS) with Kaplan-Meier or HR. Therefore, it is excluded.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Extended-release buprenorphine treatment for opioid use disorder: A mixed-methods study of response and experience. PMID 40538333 · Addiction · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance). PMID 40532782 · J Thorac Cardiovasc Surg · 2025-Oct The study is a randomized trial in oncology with time-to-event efficacy endpoints (DFS, RFS) and original results, but it does not involve a drug-containing intervention. The intervention is surgical (lobar vs. sublobar resection) and the analysis examines the extent of lymph node dissection. Therefore, it fails the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial. PMID 40523501 · J Thromb Haemost · 2025-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of a reduced-dose inactivated poliovirus vaccine versus a full-dose inactivated poliovirus vaccine in infants in Bangladesh: a double-blind, non-inferiority, randomised, controlled, phase 3 trial. PMID 40505670 · Lancet Infect Dis · 2025-Oct 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of anti-CD38 monoclonal antibodies in patients with newly diagnosed multiple myeloma: an updated systematic review and meta-analysis based on randomized controlled trials. PMID 40501427 · Leuk Lymphoma · 2025-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Construction and application of a nomogram model for predicting postoperative cerebral edema in meningiomas based on radiomics and clinical features. PMID 40474660 · Acta Radiol · 2025-Oct This is an oncology randomized trial in humans with original results, but it is excluded because the intervention is a non-drug predictive model (radiomics and clinical features) for guiding diagnosis/treatment, and it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) using Kaplan-Meier or HR.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy. PMID 40473109 · J Thorac Oncol · 2025-Oct 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1. PMID 40473108 · J Thorac Oncol · 2025-Oct The record is a randomized trial in human oncology with a drug intervention and a time-to-event endpoint (treatment-free survival). However, the phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata. Additionally, while the endpoint is time-to-event and derived from KM curves, it is treatment-free survival, which is not one of the primary/key secondary endpoints listed in the criteria (OS, PFS, DFS, EFS, RFS, TTP). Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -